News

The two companies have been co-developing a tablet-form oral insulin, IN1O5, for both type 1 and type 2 diabetes since announcing a tie-up in October 2004. This drug

During an “end-of-phase II meeting”, the FDA agreed that a single well-controlled study would be sufficient to support licensure of NOV-002 for the first-line treatment of chemotherapy-naïve, advanced

Under the contract Covalent will support Emergent BioSolutions’ development program by providing project management, study site management, field operations, data management, biostatistical services, and medical writing services. The

Based on the positive results of the trial, the company now plans to move forward with a pivotal phase III clinical development program for MC-1. In the trial

The testing will be conducted to determine whether CEL-1000 could be used as a potential treatment and/or preventive agent against this virus. CEL-1000 has previously been shown to

The results from the ongoing patient study in the UK have demonstrated that Reolysin was well-tolerated by patients and there was evidence of virus replication within several types

The mouse models have innovative modifications in certain key genes which code for proteins or enzymes known as kinases. Protein kinases have profound effects on the cells of

The phase Ib clinical trial follows previously announced preclinical data presented at a recent conference of the American Association for Cancer Research which showed that the combination of

The trial is a multicenter, multinational trial that is assessing the safety and efficacy of the drug in combination with prednisone as second-line chemotherapy in patients with the